FORWARD LOOKING STATEMENT

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the market opportunities for and the market acceptance of our products, expectations for products in development, the potential uses for our products, expected growth in revenue and market share, sustainability of performance, the expected performance of Stability Biologics as a subsidiary of MiMedx and the expected impact the acquisition will have on the MiMedx SSO strategy, the expected growth of the sales force, the availability of third-party reimbursement for our products, the strength of our patent portfolio, the ability to leverage GPO/IDN contracts to expand Stability’s product line availability, the impact of the Stability product line offering on the Company’s VA/DOD sales and international expansion, and the significance of certain clinical studies performed on the Company’s products. These statements are based on current information and belief, and are not guarantees of future performance. Our ability to predict results, financial or otherwise, or the actual effect of future plans or strategies is inherently uncertain and actual results may differ from those predicted depending on a variety of factors. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that our products may not gain the anticipated acceptance in the marketplace or that acceptance may be delayed; the effects of competition; our performance to date may not be sustainable at the same levels; MiMedx may be unable to capitalize on the complementary nature of the Stability Biologics products and the MiMedx products; the growth of Stability Biologics may not be as anticipated or the business may not otherwise perform as anticipated; the integration process is more difficult than anticipated and the anticipated benefits are not obtained in the expected timeframe or at all; we may not be able to grow our sales force as anticipated to have the desired results, or the growth may not impact revenue as anticipated; we may not be able to leverage our GPO/IDN contracts to expand Stability’s product line availability as anticipated or at all; we may not be able to protect our intellectual property and proprietary technology through patents and other means or may be subject to claims that our intellectual property or technology infringes the rights of third parties; we may not be able to commercialize products in development as expected; there may be delays or changes in reimbursement for our products; there may be delays in clinical trials or unexpected results; there may be other regulatory changes further impacting our products in the US or other countries; and the risk factors detailed from time to time in the Company’s periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the 2015 fiscal year. By making these forward-looking statements, MiMedx Group, Inc. does not undertake to update those in any manner except as may be required by the Company’s disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.
INVESTMENT HIGHLIGHTS

• Regenerative Medicine Technology
• Multiple Platform Technologies
• Strong I.P. portfolio
  – 28 Amniotic allograft patents issued and allowed, nearly 100 pending
  – Over 200 patents issued & pending for all technologies
• Over Four Years of Meeting or Exceeding Revenue Guidance with High Revenue Growth
• High Gross Profit Margins with Excellent Financial Leverage
• Experienced and Effective Management with a 5 Year Strategic Plan
• Direct and Experienced Sales Organization in Wound Care
• Building a Professional Surgical Specialty Sales Organization
  – Strategic, accretive acquisition of Stability Biologics
• Private Label Agreements with Medtronic and Zimmer
• New portfolio of products to be launched mid-year
CONSISTENT SUSTAINABLE GROWTH

18 CONSECUTIVE QUARTERS OF SEQUENTIAL GROWTH

$’s - Millions

Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1

**MISSION AND TECHNOLOGY**

MiMedx is a Regenerative Medicine Company Delivering Innovative Technologies that Enable Healing

<table>
<thead>
<tr>
<th>Placental Tissue</th>
<th>Amniotic Fluid</th>
<th>Collagen Fiber*</th>
<th>Bone Tissue</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 year Shelf Life</td>
<td>Protect &amp; Cushion</td>
<td>Mimics Native Tissue</td>
<td>Physiological Bone</td>
</tr>
<tr>
<td>Logistically Superior</td>
<td>Provide Lubrication</td>
<td>Tissue</td>
<td>Moldable</td>
</tr>
<tr>
<td>Enhance Healing</td>
<td>Reduce Inflammation</td>
<td>Biomechanics for</td>
<td>Flowable</td>
</tr>
<tr>
<td>Reduce Scar Tissue</td>
<td></td>
<td>Tendon, Ligament</td>
<td>Wet Field Integrity</td>
</tr>
<tr>
<td>Reduce Inflammation</td>
<td></td>
<td>Repair</td>
<td></td>
</tr>
</tbody>
</table>

**Amniotic**
- Enhance Healing
- Reduce Scar Tissue
- Reduce Inflammation

**Umbilical**
- Protective Environment
- Replace or Supplement Damaged or Inadequate Integumental Tissue

**Amniotic Fluid**
- Protect & Cushion
- Provide Lubrication
- Reduce Inflammation

**Collagen Fiber***
- Mimics Native Tissue
- Biomechanics for Tendon, Ligament Repair

**Bone Tissue**
- Physiological Bone
- Moldable
- Flowable
- Wet Field Integrity

*In Development – not for sale in U.S.*
GROWTH STORY CONTINUES

- 2015 Revenues of $187.3M
- 2016 Revenue Guidance of $242.5M to $250M
2016 GROWTH DRIVERS

Wound Care
- Projected Growth 25% - 30%
- Market Share Gains & Market Expansion
- Incremental Reimbursement Coverage
- Secondary City Territory Expansion

Surgical, Spine & Orthopedic (SSO)
- Projected Growth 40% - 45%
- Specialty Sales Force & Agent Network Expansion
- Stability Biologics Growth Accelerator
- GPO/IDN Contract Leverage
  - Over 5400 Hospital & Member Accounts

International Expansion

Synergistic Acquisitions
SURGICAL EXPECTED TO GROW AS LARGE AS WOUND WITHIN 5 YEARS
STABILITY BIOLOGICS ACQUISITION ACCELERATES SSO STRATEGY

Business Description
- Private company located in Nashville, Tennessee with HCT/P processing operations in San Antonio, Texas
- Regenerative medicine company focused on spine and orthopedic tissue, bone and skin allografts
- Introduced proprietary bioactive HCT/P bone graft substitute Physio® into $1.7B market

Strategic Rationale
- Stability offers complementary portfolio and intended uses for spine and orthopedic procedures not addressed by MiMedx portfolio in our SSO segment
- SB offers immediate footprint to accelerate spine expansion
- Established 100+ sales network with existing spine and orthopedic customers to rapidly expand AmnioFix® and burn product sales
- SB product platform enhances MiMedx sports medicine and foot and ankle offering with proprietary bone graft substitute and allografts
- Leverages MiMedx hospital, IDN and GPO contracts to expand Stability Biologics’ product line availability
- Broadens offering into MiMedx strong VA/DOD channel
- Furthers international expansion opportunities
Physio® Profile:
- 100% bone tissue, with no added carrier
- Physiologic microstructure retains endogenous growth factors, osteogenic proteins, and biologic CaP minerals¹
- Bioavailable growth factors (BMP 2, 7 and VEGF) via ELISA
- Significant levels² of BMP-2 via C2C12 assays³
- Retained physiologic CaP minerals have been shown previously⁴ to have inductive and osteogenic potential
- Inherent radiopacity affords clear visualization of the graft

Unparalleled Handling:
- Moldable, Blend, Flow and Form provide flexible clinical options
- Unparalleled wet field integrity assures stability and retention of the graft in the surgical field
- Microstructure affords unique handling, injection and moldability in its natural form

References:
MIMEDX U.S. MARKET OVERVIEW

**Wound Care**
- EpiFix™
- EpiFix Particulate
- EpiXL
- EpiCord™

**Surgical**
- AmnioFix®
- EpiXL
- EpiBurn
- AlloBurn™
- AmnioCord™

**Orthopedics, Spine, Sports Medicine**
- AmnioFix®
- OrthoFlo
- CollaFix™
- PhysioLogo®

**Addressable U.S. Market Size**
- **Wound Care**: $7.7B
- **Surgical**: $2.9B
- **Orthopedics, Spine, Sports Medicine**: $7.4B

**Procedure Focus**
- **Wound Care**: Diabetic Foot Ulcer, Venous Leg Ulcer, Pressure Ulcer, Trauma / Burn
- **Surgical**: Urology, OB/Gynecology, Plastic/Reconstruction, General & Colorectal
- **Orthopedics, Spine, Sports Medicine**: Spine, Hip, Knee, Foot/Ankle, Shoulder, Joint Pain, Inflammation, Cranial

**Targeted Procedures**
- **Wound Care**: 2.9 Million
- **Surgical**: 2.7 Million
- **Orthopedics, Spine, Sports Medicine**: 7.8 Million

*In Development – not for sale in U.S.*
NOT ALL AMNIOTIC MEMBRANE PRODUCTS ARE PROCESSED EQUALLY

PURION Processed dHACM contains 20 times more growth factors than competitor single layer amnion products

MULTI-CENTER COMPARATIVE EFFECTIVENESS STUDY OF HEALING DFUs USING EPIFIX®, APLIGRAF®, AND STANDARD CARE

• 12 week Multi-Center, Prospective, Randomized, Controlled, Comparative Effectiveness Trial
  - 2 week run in period with ulcers achieving ≤20% healing, remained in the trial
    - Weekly sharp debridement
    - Daily dressing changes with collagen-alginate, moist wound healing
    - Offloading with removable cast walker

• 60 Pt Study; 3 Centers:
  - 20 Patients in Standard Care arm as control receiving: debridement, moist wound healing, and offloading
  - 20 patients in EpiFix arm with weekly applications plus Standard Care
  - 20 patients in Apligraf® arm with weekly applications plus Standard Care


Apligraf® is a trademark of its owner.
CONCLUSIONS FROM THIS MULTI-CENTER, PROSPECTIVE, RANDOMIZED, CONTROLLED, COMPARATIVE EFFECTIVENESS DFU TRIAL

- Apligraf® yielded unacceptable cost and graft wastage in the trial
- MiMedx has re-evaluated the sizes of dHACM grafts it offers and will now offer additional smaller sizes to further minimize waste

<table>
<thead>
<tr>
<th>Duration</th>
<th>EpiFix % Healed</th>
<th>Apligraf® % Healed</th>
<th>Standard Care % Healed</th>
<th>EpiFix Vs. Apligraf®</th>
<th>EpiFix Vs. Standard Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 weeks</td>
<td>85%</td>
<td>35%</td>
<td>30%</td>
<td>P=0.001</td>
<td>P=0.001</td>
</tr>
<tr>
<td>6 weeks</td>
<td>95%</td>
<td>45%</td>
<td>35%</td>
<td>P=0.0006</td>
<td>P=0.0001</td>
</tr>
</tbody>
</table>

- Trial showed clinical superiority of EpiFix® over both Apligraf® and Standard Care in completed healing of DFUs at 4 and 6 weeks

<table>
<thead>
<tr>
<th>Product</th>
<th>Total # of Grafts purchased</th>
<th>Mean Grafts Used per Patient</th>
<th>Total cm² of Grafts Purchased</th>
<th>Total cm² of Grafts Applied</th>
<th>Total Cost of Grafts Applied</th>
<th>Average Patient Graft Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apligraf®</td>
<td>124</td>
<td>6.2</td>
<td>5,546</td>
<td>159</td>
<td>$184,315</td>
<td>$9,216</td>
</tr>
<tr>
<td>EpiFix®</td>
<td>43</td>
<td>2.15</td>
<td>154</td>
<td>68</td>
<td>$ 33,379</td>
<td>$1,669</td>
</tr>
</tbody>
</table>

69 YEAR OLD FEMALE: MOHS SURGERY PATIENT

Application of EpiFix 2x3 cm

Day 1

Week 2

Week 3

Week 4

10 months

Photos courtesy of John Marascalco, MD
KELOID REMOVAL, ABDOMINAL INCISION

Pre-Op

Post-scar revision using EpiFix on 1/3 portion of original scar

Scar after EpiFix use

- Scar revision in a keloid forming patient.
- A portion of the scar was revised and the area treated with EpiFix®.
- Scar did not recur at the treatment site after one year of observation.
FACELIFT DEHISCENCE: 30 DAYS POST OP

• 75 year old with a History of Diabetes, Hypertension, Cancer and Mitral Valve Prolapse.
• Medications include: Metformin, Trazodone, Nexium, Lovastatin, Gabapentin, Lisinopril, Actos, others.
• Standard of Care for One Month Post Facelift.
• Doctor and Patient Elected to place EpiFix Amniotic Membrane Allografts at One Month post face lift
• Patient was Healed at One Month post EpiFix Application
GPO / IDN CONTRACTS

• 5 Group Purchasing Organizations (GPO) contracts in place
  – 4 have 80% or sole commitment tiers for Amniotic Tissue/Skin Substitute
  – We have contracts with the 4 largest GPO’s
  – Includes both AmnioFix & EpiFix
  – Covers approximately 4000 hospitals
  – Recipient of Novation Innovative Technology Award for 2015

• 40 Integrated Delivery Networks (IDN) Contracts
  – All include both AmnioFix & EpiFix
  – Covers approximately 1300 hospitals
  – Many have committed Amniotic Tissue contracts
  – 1 major IDN has just signed a Sole Amniotic commitment with us
SALES FORCE

• Direct Sales Force
  – Federal Team
  – Commercial Wound Care Team

• Distributor & Sales Agent
  – Surgical, Sports Medicine and Orthopedics

Team Meeting Picture
January 2016

~250 Sales Professionals